Syndax Pharmaceuticals (SNDX) Share-based Compensation (2015 - 2026)

Syndax Pharmaceuticals' Share-based Compensation history runs 12 years deep, the most recent figure standing at $12.1 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 16.12% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $49.2 million (up 10.49% YoY), while the FY2025 annual figure was $47.5 million, up 10.41% from the prior year.
• Share-based Compensation was $12.1 million for Q1 2026 at Syndax Pharmaceuticals, up from $11.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $13.8 million in Q2 2025 to a low of $3.5 million in Q1 2022.
• Historically, Share-based Compensation has averaged $8.8 million across 5 years, with a median of $8.9 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation surged 104.8% in 2023, then declined 8.48% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $4.2 million in 2022, then jumped by 96.35% to $8.3 million in 2023, then jumped by 47.68% to $12.3 million in 2024, then dropped by 8.48% to $11.3 million in 2025, then rose by 7.1% to $12.1 million in 2026.
• The last three Share-based Compensation figures came in at $12.1 million (Q1 2026), $11.3 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.